Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...

New Study Shows at-Home Colon Cancer Screening Test Reduces Risk of Colorectal Cancer Death, as Effective as Screening Colonoscopy July 25, 2024 — A noninvasive colorectal cancer screening test ...

But MSD will have to play its cards right to gain access to England’s lung cancer market – as Keytruda received its own draft rejection in second line NSCLC two weeks ago. Speaking to ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

Cercek says, younger people with colorectal cancer notice bright red blood on their toilet paper. That’s because their tumors commonly develop in the last portion of the colon or in the rectum ...

Many health conditions can affect the descending colon, including inflammatory bowel disease (IBD), colon cancer, colonic perforation, and diverticulitis. The colon helps the body absorb water and ...

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today ...